Free Trial

TransMedics Group Q1 2023 Earnings Report

TransMedics Group logo
$73.40 +5.13 (+7.51%)
As of 01:22 PM Eastern

TransMedics Group EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.17
One Year Ago EPS
-$0.38

TransMedics Group Revenue Results

Actual Revenue
$41.60 million
Expected Revenue
$36.05 million
Beat/Miss
Beat by +$5.55 million
YoY Revenue Growth
+161.60%

TransMedics Group Announcement Details

Quarter
Q1 2023
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Remove Ads

TransMedics Group Earnings Headlines

DOGE Social Security bombshell?
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
See More TransMedics Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TransMedics Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransMedics Group and other key companies, straight to your email.

About TransMedics Group

TransMedics Group (NASDAQ:TMDX), a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

View TransMedics Group Profile

More Earnings Resources from MarketBeat